Wakelee H - Search Results

1

Second- and third-line treatments in non-small cell lung cancer.

Kumar A, Wakelee H. Kumar A, et al. Among authors: wakelee h. Curr Treat Options Oncol. 2006 Jan;7(1):37-49. doi: 10.1007/s11864-006-0030-9. Curr Treat Options Oncol. 2006. PMID: 16343367 Review.

2

Novel approaches for the treatment of small cell lung cancer.

Wakelee H, Kelly K. Wakelee H, et al. Hematol Oncol Clin North Am. 2004 Apr;18(2):499-518. doi: 10.1016/j.hoc.2004.01.001. Hematol Oncol Clin North Am. 2004. PMID: 15094184 Review. No abstract available.

3

Docetaxel in advanced non-small cell lung cancer.

Wakelee H, Ramalingam S, Belani CP. Wakelee H, et al. Expert Rev Anticancer Ther. 2005 Feb;5(1):13-24. doi: 10.1586/14737140.5.1.13. Expert Rev Anticancer Ther. 2005. PMID: 15757434 Review.

4

Post-operative radiotherapy (PORT) or chemoradiotherapy (CPORT) following resection of stages II and IIIA non-small cell lung cancer (NSCLC) does not increase the expected risk of death from intercurrent disease (DID) in Eastern Cooperative Oncology Group (ECOG) trial E3590.

Wakelee HA, Stephenson P, Keller SM, Wagner H, Herskovic A, Komaki R, Marks RS, Perry MC, Livingston RB, Johnson DH; Eastern Cooperative Oncology Group. Wakelee HA, et al. Lung Cancer. 2005 Jun;48(3):389-97. doi: 10.1016/j.lungcan.2004.11.007. Epub 2005 Jan 5. Lung Cancer. 2005. PMID: 15893008 Clinical Trial.

5

Targeting angiogenesis with vascular endothelial growth factor receptor small-molecule inhibitors: novel agents with potential in lung cancer.

Wakelee HA, Schiller JH. Wakelee HA, et al. Clin Lung Cancer. 2005 Sep;7 Suppl 1:S31-8. doi: 10.3816/clc.2005.s.005. Clin Lung Cancer. 2005. PMID: 16159417 Review.

6

Activity of novel cytotoxic agents in lung cancer: epothilones and topoisomerase I inhibitors.

Wakelee HA, Sikic BI. Wakelee HA, et al. Clin Lung Cancer. 2005 Sep;7 Suppl 1:S6-12. doi: 10.3816/clc.2005.s.002. Clin Lung Cancer. 2005. PMID: 16159420 Review.

7

Optimizing first-line treatment options for patients with advanced NSCLC.

Wakelee H, Belani CP. Wakelee H, et al. Oncologist. 2005;10 Suppl 3:1-10. doi: 10.1634/theoncologist.10-90003-1. Oncologist. 2005. PMID: 16368866 Free article. Review.

8

Changes in the natural history of nonsmall cell lung cancer (NSCLC)--comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group trials before and after 1990.

Wakelee HA, Bernardo P, Johnson DH, Schiller JH. Wakelee HA, et al. Cancer. 2006 May 15;106(10):2208-17. doi: 10.1002/cncr.21869. Cancer. 2006. PMID: 16604529 Free article.

9

Sunitinib: a newly approved small-molecule inhibitor of angiogenesis.

Cabebe E, Wakelee H. Cabebe E, et al. Among authors: wakelee h. Drugs Today (Barc). 2006 Jun;42(6):387-98. doi: 10.1358/dot.2006.42.6.985633. Drugs Today (Barc). 2006. PMID: 16845442 Review.

10

Current status of adjuvant chemotherapy for stage IB non-small-cell lung cancer: implications for the New Intergroup Trial.

Wakelee HA, Schiller JH, Gandara DR. Wakelee HA, et al. Clin Lung Cancer. 2006 Jul;8(1):18-21. doi: 10.3816/CLC.2006.n.028. Clin Lung Cancer. 2006. PMID: 16870041 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

357 results

Search Page

Filters